ReviewDrugs2015
Clinical association between pharmacogenomics and adverse drug reactions.
Review in Drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 73 citations in OpenAlex.
- A review on adverse drug reaction related to medication in health sector: an account of what we have discovered and implemented-pharmacovigilance.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- GWAS study of myelosuppression among NSCLC patients receiving platinum-based combination chemotherapy.Acta biochimica et biophysica Sinica · 2025Article
- Prediction of adverse drug reactions based on pharmacogenomics combination features: a preliminary study.Frontiers in pharmacology · 2025Article
- Clinicians' experience on the effectiveness of pharmacotherapy in patients with first-episode depression: a randomized controlled trial based on pharmacogenomics.Frontiers in pharmacology · 2025Article
- Genetic diversity of variants involved in drug response among Tunisian and Italian populations toward personalized medicine.Scientific reports · 2024Article
- Transfer learning enhanced graph neural network for aldehyde oxidase metabolism prediction and its experimental application.Acta pharmaceutica Sinica. B · 2024Article
- Longitudinal Influence of Prescribed Antidepressants on Fecal and Oral Microbiomes Among Veterans With Major Depressive Disorder.The Journal of neuropsychiatry and clinical neurosciences · 2024Article
- Structure-activity relationships andz interindividual variability of drug responses: pharmacogenomics with antimicrobial drugs as a paradigm.The Journal of international medical research · 2023Review
- The relationship between sensory processing sensitivity and medication sensitivity: brief report.Frontiers in psychology · 2023Article
- Calculation of the pharmacogenomics benefit score for patients with medication-related problems.Frontiers in genetics · 2023Article
- Pharmacogenomic Profile of Amazonian Amerindians.Journal of personalized medicine · 2022Article
- Pharmacogenetic distinction of the Croatian population from the European average.Croatian medical journal · 2022Article
- Personalized Management and Treatment of Alzheimer's Disease.Life (Basel, Switzerland) · 2022Review
- Pharmacogenomics-Guided Pharmacotherapy in Patients with Major Depressive Disorder or Bipolar Disorder Affected by Treatment-Resistant Depressive Episodes: A Long-Term Follow-Up Study.Journal of personalized medicine · 2022Article
- Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.NPJ genomic medicine · 2022Article
- Ten Years of Experience Support Pharmacogenetic Testing to Guide Individualized Drug Therapy.Pharmaceutics · 2022Article
- Pharmacogenomics of Alzheimer's Disease: Novel Strategies for Drug Utilization and Development.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Sub-Analysis of CYP-GUIDES Data: Assessing the Prevalence and Impact of Drug-Gene Interactions in an Ethnically Diverse Cohort of Depressed Individuals.Frontiers in pharmacology · 2022Article
- Genetic analysis of pharmacogenomic VIP variants in the Wa population from Yunnan Province of China.BMC genomic data · 2021Article
- A novel machine learning-based approach for the computational functional assessment of pharmacogenomic variants.Human genomics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adverse drug reactions (ADRs) are a major public health concern and cause significant patient morbidity and mortality. Pharmacogenomics is the study of how genetic polymorphisms affect an individual's response to pharmacotherapy at the level of a whole genome. This article updates our knowledge on how genetic polymorphisms of important genes alter the risk of ADR occurrence after an extensive literature search. To date, at least 244 pharmacogenes identified have been associated with ADRs of 176 clinically used drugs based on PharmGKB. At least 28 genes associated with the risk of ADRs have been listed by the Food and Drug Administration as pharmacogenomic biomarkers. With the availability of affordable and reliable testing tools, pharmacogenomics looks promising to predict, reduce, and minimize ADRs in selected populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.